{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+2-+Dose+Expansion&page=8", "query": { "intervention": "Arm 2- Dose Expansion", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 405, "total_pages": 41, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+2-+Dose+Expansion&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+2-+Dose+Expansion&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T13:43:37.425Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03342937", "title": "KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "Esophagus Cancer" ], "interventions": [ { "name": "Oxaliplatin+Capecitabine+Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2018-01-11", "completion_date": "2023-02-06", "has_results": true, "last_update_posted_date": "2024-03-13", "last_synced_at": "2026-10-14T13:43:37.425Z", "location_count": 7, "location_summary": "Clayton, North Carolina • Durham, North Carolina • Henderson, North Carolina + 4 more", "locations": [ { "city": "Clayton", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Henderson", "state": "North Carolina" }, { "city": "Laurinburg", "state": "North Carolina" }, { "city": "Lumberton", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03342937" }, { "nct_id": "NCT04557449", "title": "Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liposarcoma", "Prostate Cancer", "Breast Neoplasms", "Adenocarcinoma of Lung" ], "interventions": [ { "name": "PF-07220060", "type": "DRUG" }, { "name": "Letrozole", "type": "COMBINATION_PRODUCT" }, { "name": "Fulvestrant", "type": "COMBINATION_PRODUCT" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Enzalutamide", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 362, "start_date": "2020-09-23", "completion_date": "2027-11-23", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-14T13:43:37.425Z", "location_count": 14, "location_summary": "Los Angeles, California • New Haven, Connecticut • Trumbull, Connecticut + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04557449" }, { "nct_id": "NCT04261439", "title": "A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "In Escalation: All Patients With Solid Tumors and Lymphoma", "In Expansion: Melanoma, Non-small Cell Lung Cancer" ], "interventions": [ { "name": "NIZ985", "type": "DRUG" }, { "name": "Spartalizumab", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2020-02-27", "completion_date": "2023-12-27", "has_results": false, "last_update_posted_date": "2025-05-06", "last_synced_at": "2026-10-14T13:43:37.425Z", "location_count": 2, "location_summary": "Duarte, California • La Jolla, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04261439" }, { "nct_id": "NCT05458219", "title": "A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Unresectable or Metastatic Solid Tumors" ], "interventions": [ { "name": "IBI343", "type": "DRUG" }, { "name": "FOLFIRINOX/mFOLFIRINOX", "type": "DRUG" }, { "name": "mFOLFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 470, "start_date": "2022-10-26", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-14T13:43:37.425Z", "location_count": 3, "location_summary": "Austin, Texas • Irving, Texas • San Antonio, Texas", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "Irving", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05458219" }, { "nct_id": "NCT02824575", "title": "Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Breast Adenocarcinoma", "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "Recurrent Breast Carcinoma", "Stage IV Breast Cancer" ], "interventions": [ { "name": "Rebastinib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Eribulin Mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 28, "start_date": "2016-07", "completion_date": "2021-12-27", "has_results": false, "last_update_posted_date": "2022-04-04", "last_synced_at": "2026-10-14T13:43:37.425Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02824575" }, { "nct_id": "NCT06546553", "title": "A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Non-small-cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Renal Cell Carcinoma", "Colorectal Carcinoma", "Ovarian Carcinoma" ], "interventions": [ { "name": "PF-07826390", "type": "DRUG" }, { "name": "sasanlimab", "type": "BIOLOGICAL" }, { "name": "SOC (anti-PD-1 + platinum -based chemo)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2024-09-06", "completion_date": "2025-10-03", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-10-14T13:43:37.425Z", "location_count": 8, "location_summary": "Beverly Hills, California • Fort Myers, Florida • Orlando, Florida + 4 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06546553" }, { "nct_id": "NCT04449874", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Colorectal Cancer", "Advanced Solid Tumors" ], "interventions": [ { "name": "GDC-6036", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "GDC-1971", "type": "DRUG" }, { "name": "Inavolisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 498, "start_date": "2020-07-29", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-14T13:43:37.425Z", "location_count": 9, "location_summary": "Duarte, California • La Jolla, California • Orange, California + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04449874" }, { "nct_id": "NCT07162038", "title": "Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Malignancies", "Hematologic Neoplasms" ], "interventions": [ { "name": "mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL)", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "CD19 Flow Cytometry Assay", "type": "DEVICE" }, { "name": "CD19 Immunohistochemical Assay", "type": "DEVICE" }, { "name": "Total Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 155, "start_date": "2025-11-14", "completion_date": "2034-10-01", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-14T13:43:37.425Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07162038" }, { "nct_id": "NCT02094625", "title": "NAC to Prevent Cisplatin-induced Hearing Loss", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroectodermal Tumors, Primitive", "Liver Neoplasms", "Osteosarcoma", "Other Childhood Cancers Using Cisplatin-based Regimens" ], "interventions": [ { "name": "N-Acetylcysteine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 52, "start_date": "2016-03", "completion_date": "2021-08", "has_results": false, "last_update_posted_date": "2023-04-18", "last_synced_at": "2026-10-14T13:43:37.425Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02094625" }, { "nct_id": "NCT05109975", "title": "A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Debio 0123", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 93, "start_date": "2021-11-05", "completion_date": "2026-04-24", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-14T13:43:37.425Z", "location_count": 4, "location_summary": "Grand Rapids, Michigan • New York, New York • San Antonio, Texas + 1 more", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05109975" } ] }